Early trial tests re-engineered immune cells to fight stubborn blood cancer
NCT ID NCT05577000
Summary
This is an early-stage study to check the safety of a new cell therapy for multiple myeloma, a type of blood cancer, that has come back or stopped responding to other treatments. Doctors will collect a small number of patients' own immune cells, modify them in a lab to better target the cancer, and then infuse them back. The main goals are to find a safe dose and see if the treatment causes any serious side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.